PHA Classroom banner

PHA Classroom has moved! Visit

>>Back to All Recordings

>>Back to About PH Recordings
>>Back to 2012 Conference Session Recordings

Session Recording from PHA's 2012 10th International PH Conference
PAH Drug Development: The Pipeline Runneth Over

June 23, 2012

There are now nine approved PAH drugs in the U.S., several of which are available in multiple formulations. At least eight more drugs are currently in development. We will discuss how the newer drugs will impact drug selection for an individual patient.

Presenter Information

Mardi Gomberg-Maitland, MD, MSc, University of Chicago Medical Center, Chicago, Ill. (Chair); Sonja Bartolome, MD, FCCP, UT Southwestern Medical Center, Dallas, Texas; Donneea Edwards-Moore, RN, MSN, University of Chicago Medical Center, Chicago, Ill.; Fernando Torres, MD, UT Southwestern Medical Center, Dallas, Texas; Jason Yuan, MD, PhD, University of Illinois at Chicago, Chicago, Ill.








Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. Bayer HealthCare United Therapeutics Corporation
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.